account_id none on file
legal_name none on file
ticker CVAC
cik none on file
domain curevac.com
linkedin_company_url https://www.linkedin.com/company/curevac
entry_point_account_id none on file
name CureVac N.V.
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 60 executives 0 family 0
why_nownone on file
callsnone on file
filings
= First Patient Dosed
ir_statement / Aug 8, 2026 / receipt
= New strategic collaboration
ir_statement / Aug 8, 2026 / receipt
Oncology Pipeline: Significant Progress and Expansion in 2022
ir_statement / Aug 8, 2026 / receipt
Phase 1 (5 First-in-Human)
ir_statement / Aug 8, 2026 / receipt
Dose expansion tested in multiple cancer types including:
ir_statement / Aug 8, 2026 / receipt
MoA Designed to Allow Higher Dosing & Longer Duration ofTreatmentwithONC-392
ir_statement / Aug 8, 2026 / receipt
Monotherapy RP2D: 10 mg/kg, Combination RP2D: 6 mg/kg
ir_statement / Aug 8, 2026 / receipt
Preliminary data demonstrated lower irAE rate than observed for comparable IO or IO-IO combinations
ir_statement / Aug 8, 2026 / receipt
Safety profile of ONC-392 allows for higher dosing and longer duration of treatment in monotherapy and in combination with pembrolizumab
ir_statement / Aug 8, 2026 / receipt
= Label expansion//product launch
ir_statement / Aug 8, 2026 / receipt
10+ other infectious disease programs
ir_statement / Aug 8, 2026 / receipt
Infectious Disease Pipeline: Expansion in 2022
ir_statement / Aug 8, 2026 / receipt
executivesnone on file
familynone on file
upcomingnone on file
changesnone on file
mcp_package_hint
slug curevac-n-v
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$